Karyopharm Therapeutics Inc (KPTI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $394,660
Last updated: Nov 10, 2026 at 7:59 PM ET
Karyopharm Therapeutics Inc (KPTI) Stock Forecast
Analysts expect Karyopharm Therapeutics (KPTI) to earn -$5.68 per share in the fiscal year ending Dec 31, 2026, on revenue of $135.22M. Of 5 analysts, 4 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 1.80, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 80% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 40.0% |
| Buy | 2 | 40.0% |
| Hold | 1 | 20.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 27.7%.
- Fiscal year ending Dec 31, 2026
- -$5.68
- EPS consensus, revenue $135.22M
- Fiscal year ending Dec 31, 2027
- -$1.92
- EPS consensus, revenue $172.74M
- Next report
- Feb 10, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$5.68 | -$5.68 to -$5.68 | 1 | $135.22M | $130.93M to $137.72M | 4 |
| Dec 31, 2027 | -$1.92 | -$1.92 to -$1.92 | 1 | $172.74M | $155.79M to $198.43M | 3 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.62 | -$0.83 to -$0.33 | 5 | $34.65M | $32.49M to $37.03M | 5 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 3 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 1 |
| Fiscal year ending Dec 31, 2027 | 2 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$4.76.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$5.68 | -$5.85 | -$5.85 | -$5.85 | -$4.76 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.92 | -$2.82 | -$2.82 | -$2.82 | -$3.21 | N/A |
Frequently Asked Questions About KPTI
What is the KPTI stock forecast?
Consensus analyst estimates put Karyopharm Therapeutics's EPS at -$5.68 for the fiscal year ending Dec 31, 2026, on revenue of $135.22M. The consensus rating from 5 analysts is Buy.
How do analysts rate KPTI stock?
Of 5 analysts covering Karyopharm Therapeutics, 2 rate it Strong Buy, 2 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from KPTI next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$5.68, with estimates from -$5.68 to -$5.68 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.92, with estimates from -$1.92 to -$1.92 from 1 analyst.
What revenue do analysts expect from Karyopharm Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $135.22M, with estimates from $130.93M to $137.72M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $172.74M, with estimates from $155.79M to $198.43M.
How many analysts cover KPTI?
5 analysts rate Karyopharm Therapeutics stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
KPTI pages: Overview, Earnings, Forecast, Financials, Competitors